CADTH | Evidence Driven
CADTH | Evidence Driven

fluticasone furoate/umeclidinium bromide/vilanterol trifenatate

Details

Generic Name:
fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
Project Status:
Not filed
Therapeutic Area:
Asthma, maintenance
Manufacturer:
GlaxoSmithKline Inc.
Brand Name:
Trelegy Ellipta
Project Line:
Reimbursement Review
Project Number:
N/A
Manufacturer Requested Reimbursement Criteria1:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer.
Submission Type:
Non Submission
Indications:
Long-term, once-daily, maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a maintenance combination of a medium or high dose of an ICS and a LABA.
Recommendation Type:
CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 16, 2023